A Pharmacological Update and Safety Analysis of Medications for Smoking Cessation: Which Ones to Use?

Basit Öğe Kaydı
dc.authorid0000-0003-1659-4723
dc.contributor.authorAkman, Canan
dc.contributor.authorAkgun, Feride Sinem
dc.contributor.authorOzel, Betul Akbuga
dc.contributor.authorOzkaya, Bilgen
dc.contributor.authorOzturk, Goksu Afacan
dc.contributor.authorKarcioglu, Ozgur
dc.date.accessioned2026-02-03T12:00:20Z
dc.date.available2026-02-03T12:00:20Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractInterventions to reduce smoking prevalence aim to help patients quit smoking to cut down its hazards and related impairments in human beings. Pharmacological treatments are recommended for those with high levels of addiction because of severe physical and psychological dependence. Use of pharmacotherapy can double the odds of successful quitting. Nicotine replacement therapy (NRT), drug treatment regimens including nicotinic receptor agonists (varenicline), dopamine and norepinephrine reuptake inhibitors (bupropion), cytisinicline (cytisine), and combination therapy (NRT + medication) can be employed on a case-by-case basis. Furthermore, varenicline has been found to be more effective than the other agents in most studies. The most common adverse effects of pharmacological agents include depression, nausea, anxiety, abnormal dreams, and insomnia. On the other hand, electronic cigarettes offer another alternative to aid in smoking cessation (SC). Endurance of SC is mostly related to the employment of combined approaches, such as counselling and pharmacotherapy. This study is designed to provide an up-to-date overview of the contemporary approach to interventions aimed at helping patients in SC.
dc.identifier.doi10.2174/0113816128418550251030044713
dc.identifier.issn1381-6128
dc.identifier.issn1873-4286
dc.identifier.pmid41487010
dc.identifier.scopus2-s2.0-105026474939
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.2174/0113816128418550251030044713
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34553
dc.identifier.wosWOS:001653331600001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCurrent Pharmaceutical Design
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20260130
dc.subjectSmoking cessation
dc.subjectnicotine dependence
dc.subjectnicotinic receptor agonists
dc.subjectvarenicline
dc.subjectbupropion
dc.subjectcytisinicline
dc.subjectelectronic cigarettes
dc.titleA Pharmacological Update and Safety Analysis of Medications for Smoking Cessation: Which Ones to Use?
dc.typeReview

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu